Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index (AMEX:RSY)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index Charts. Click Here for more Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index Charts.](/p.php?pid=staticchart&s=A%5ERSY&p=8&t=15)
Recom Managed Systems, Inc. (AMEX: RSY), a life-sciences
company developing patented heart-monitoring technology, announced
today that Rajiv Singh, a systems engineer with more than 25 years of
experience in business development, program management and
infrastructure, container, and port security technology, has signed on
as a consultant to the company.
"Rajiv's impressive background in engineering and business
development for some of the leading technology companies in the world
make him an ideal fit for Recom," said Pamela Bunes, Recom's president
and chief executive officer. "His counsel and dedicated support will
be of tremendous benefit as we continue to advance the company's
proprietary technology."
In his role at Recom, Mr. Singh will identify additional
applications for Recom's biomedical signal-processing platform and
guide the progress of the Model 100 Heart Monitor from the
research-and-development phase through the contract manufacturing
process and into market commercialization. Mr. Singh also will help
facilitate interdepartment communications to ensure that clinician
feedback is integrated into future Recom products.
"Recom has developed a ground-breaking technology with the
potential to revolutionize the practice of cardiac monitoring," said
Mr. Singh. "I look forward to the opportunity to work with the company
at this exciting phase, as we prepare to bring the Model 100 to
market."
Most recently, Mr. Singh was director of business development for
L3 Communications, where he was responsible for expanding the
company's programs in critical infrastructure, container and
waterside/port security. He has also held positions with Logicon
Syscon and Earth Tech. He holds master's degrees in computer science
and management from Johns Hopkins University and a master's degree in
engineering from Southern Illinois University. Mr. Singh lives in
Ellicott City, Md.
Breakthrough ECG Monitoring Technology
Recom's first product, the Model 100 Heart Monitor, is an
ambulatory patient heart monitor that uses patented signal-processing
technology to record a clinical-quality ECG signal in the presence of
"noise," or interference, generated by the patient's body movements
and ambient environment. By reducing these interfering factors during
recordings, the Recom Model 100 helps family practitioners, internists
and cardiologists more accurately detect cardiac abnormalities or
changes that may occur during daily activities and allows medical
experts to collect extensive, continuous cardiac data over time, which
can establish a baseline against which future readings can be
compared. The Model 100 provides up to 48 hours of real-time heart
monitoring during patients' everyday activities. The Model 100 has
received 510(k) clearance from the Food and Drug Administration (FDA).
About Recom Managed Systems, Inc.
Recom Managed Systems, Inc. is an emerging life-sciences company
focused on the monitoring and detection of disease through continuous
biomedical signal monitoring. Recom Managed Systems, Inc. uses its
patented signal technology to design and develop medical devices that
simplify and reduce the costs of diagnostic testing and patient
monitoring in an ambulatory setting. With our patented
signal-technology platform, Recom brings clinical-quality
physiological signal monitoring to the ambulatory setting.
Recom Managed Systems, Inc. is traded on the American Stock
Exchange under the symbol RSY. More information is located at
http://www.recom-systems.com.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are
"forward-looking" statements. Forward-looking statements involve known
and unknown risks, which may cause Recom's actual results in the
future to differ materially from expected results. Factors which could
cause or contribute to such differences include, but are not limited
to, failure to complete the development and introduction of new
products or services, failure to obtain federal or state regulatory
approvals governing medical devices, monitoring and other related
services or products, inability to obtain physician, patient or
insurance acceptance of Recom's products or services, adverse
equity-market conditions and declines in the value of Recom's common
stock, and the unavailability of financing to complete management's
plans and objectives. These risks are qualified in their entirety by
cautionary language and risk factors set forth and to be further
described in Recom's filings with the Securities and Exchange
Commission.